Role of CD24 in anoikis resistance of ovarian cancer cells

Abstract

This study examined the effect of CD24 on anoikis of ovarian cancer cells. The expression of CD24 was detected by RT-PCR and Western blotting in ovarian cancer cells with high metastatic potential (HO-8910PM cells) and low metastatic potential (A2780 cells). Cell viability and cell proliferation were detected by MTT assay in suspension culture and adhesion culture. Soft agar culture was used to observe the colony formation. Anoikis was flow cytometrically detected. The results showed that the expression levels of CD24 mRNA and protein were significantly higher in HO-8910PM cells than in A2780 cells (P<0.01). In the suspension culture and soft agar culture, the HO-8910PM cells formed larger and more colonies (35.33±5.51 vs. 16.67±4.04; P<0.01), and showed a stronger resistance to anoikis than A2780 cells did (cell apoptosis rate: 5.93%±2.38% vs. 16.32%±2.00%; P<0.01). After treated with CD24 monoclonal antibodies, the number of colony formed in HO-8910PM and A2780 cells was significantly decreased (9.33±2.52 and 8.00±2.00, respectively), and the anoikis rate of the two cell lines was also markedly increased (23.11%±2.87% and 28.36%±2.29%, respectively). Our study suggested that CD24 may play an important role in the development of anoikis resistance and CD24 can be used as a new therapeutic target to induce anoikis and inhibit metastasis in ovarian cancer.

Keywords

ovarian cancer / CD24 / anoikis resistance / metastasis

References

[1] SiegelR, NaishadhamD, JemalA. Cancer statistics, 2013. CA Cancer J Clin, 2013, 63(1): 11-30 PMID: 23335087

[2] ChoKR, ShihIM. Ovarian cancer. Annu Rev Pathol, 2009, 4: 287-313 PMCID: 2679364 PMID: 18842102

[3] HunnJ, RodriguezGC. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol, 2012, 55(1): 3-23 PMID: 22343225

[4] JaysonGC, KohnEC, KitchenerHC, et al. . Ovarian cancer. Lancet, 2014, 384(9951): 1376-1388 PMID: 24767708

[5] KigawaJ. New strategy for overcoming resistance to chemotherapy of ovarian cancer. Yonago Acta Med, 2013, 56(2): 43-50 PMCID: 3771207 PMID: 24031151

[6] FrischSM, FrancisH. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol, 1994, 124(4): 619-626 PMID: 8106557

[7] TanK, GoldsteinD, CroweP, et al. . Uncovering a key to the process of metastasis in human cancers: a review of critical regulators of anoikis. J Cancer Res Clin Oncol, 2013, 139(11): 1795-1805 PMID: 23912151

[8] TaddeiML, GiannoniE, FiaschiT, et al. . Anoikis: an emerging hallmark in health and diseases. J Pathol, 2012, 226(2): 380-393 PMID: 21953325

[9] PaoliP, GiannoniE, ChiarugiP. Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta, 2013, 1833(12): 3481-3498 PMID: 23830918

[10] Maamer-AzzabiA, Ndozangue-TouriguineO, BréardJ. Metastatic SW620 colon cancer cells are primed for death when detached and can be sensitized to anoikis by the BH3-mimetic ABT-737. Cell Death Dis, 2013, 4: e801 PMCID: 3789186 PMID: 24030153

[11] SchackmannRC, KlarenbeekS, VlugEJ, et al. . Loss of p120-catenin induces metastatic progression of breast cancer by inducing anoikis resistance and augmenting growth factor receptor signaling. Cancer Res, 2013, 73(15): 4937-4949 PMID: 23733751

[12] ChengKW, LahadJP, KuoWL, et al. . The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med, 2004, 10(11): 1251-1256 PMID: 15502842

[13] SoodAK, Armaiz-PenaGN, HalderJ, et al. . Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest, 2010, 120(5): 1515-1523 PMCID: 2860925 PMID: 20389021

[14] HeX, OtaT, LiuP, et al. . Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells. Cancer Res, 2010, 70(8): 3109-3118 PMID: 20388781

[15] KristiansenG, SammarM, AltevogtP. Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol, 2004, 35(3): 255-262 PMID: 15339045

[16] KristiansenG, DenkertC, SchlünsK, et al. . CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol, 2002, 161(4): 1215-1221 PMCID: 1867310 PMID: 12368195

[17] KristiansenG, WinzerKJ, MayordomoE, et al. . CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res, 2003, 9(13): 4906-4913 PMID: 14581365

[18] KangKS, ChoiYP, GaoMQ, et al. . CD24+ ovary cancer cells exhibit an invasive mesenchymal phenotype. Biochem Biophys Res Commun, 2013, 432(2): 333-338 PMID: 23396061

[19] HodeibM, EskanderRN, BristowRE. New paradigms in the surgical and adjuvant treatment of ovarian cancer. Minerva Ginecol, 2014, 66(2): 179-192 PMID: 24848076

[20] LengyelE. Ovarian cancer development and metastasis. Am J Pathol, 2010, 177(3): 1053-1064 PMCID: 2928939 PMID: 20651229

[21] Aguirre-GhisoJA, BragadoP, SosaMS. Metastasis awakening: targeting dormant cancer. Nat Med, 2013, 19(3): 276-277 PMCID: 3651698 PMID: 23467238

[22] ZhongX, RescorlaFJ. Cell surface adhesion molecules and adhesion-initiated signaling: understanding of anoikis resistance mechanisms and therapeutic opportunities. Cell Signal, 2012, 24(2): 393-401 PMID: 22024283

[23] MehlenP, PuisieuxA. Metastasis: a question of life or death. Nat Rev Cancer, 2006, 6(6): 449-458 PMID: 16723991

[24] KristiansenG, PilarskyC, PervanJ, et al. . CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate, 2004, 58(2): 183-192 PMID: 14716744

[25] Karimi-BusheriF, Rasouli-NiaA, ZadorozhnyV, et al. . CD24+/CD38- as new prognostic marker for non-small cell lung cancer. Multidiscip Respir Med, 2013, 8(1): 65 PMCID: 3844723 PMID: 24094028

[26] ChouYY, JengYM, LeeTT, et al. . Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma. Ann Surg Oncol, 2007, 14(10): 2748-2758 PMID: 17680316

[27] ChoiYL, KimSH, ShinYK, et al. . Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors. Gynecol Oncol, 2005, 97(2): 379-386 PMID: 15863133

[28] MoullaA, MiliarasD, SiogaA, et al. . The immunohistochemical expression of CD24 and CD171 adhesion molecules in borderline ovarian tumors. Pol J Pathol, 2013, 64(3): 180-184 PMID: 24166603

[29] AignerS, RuppertM, HubbeM, et al. . Heat stable antigen (mouse CD24) supports myeloid cell binding to endothelial and platelet P-selectin. Int Immunol, 1995, 7(10): 1557-1565 PMID: 8562500

[30] AignerS, SthoegerZM, FogelM, et al. . CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood, 1997, 89(9): 3385-3395 PMID: 9129046

[31] AignerS, RamosCL, Hafezi-MoghadamA, et al. . CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J, 1998, 12(12): 1241-1251 PMID: 9737727

[32] BaumannP, CremersN, KroeseF, et al. . CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res, 2005, 65(23): 10783-10793 PMID: 16322224

[33] ShieldK, AcklandML, AhmedN, et al. . Multicellular spheroids in ovarian cancer metastases: Biology and pathology. Gynecol Oncol, 2009, 113(1): 143-148 PMID: 19135710

[34] SodekKL, RinguetteMJ, BrownTJ. Compact spheroid formation by ovarian cancer cells is a ssociated with contractile behavior and an invasive phenotype. Int J Cancer, 2009, 124(9): 2060-2070 PMID: 19132753

[35] FriederichsJ, ZellerY, Hafezi-MoghadamA, et al. . The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. Cancer Res, 2000, 60(23): 6714-6722 PMID: 11118057

[36] SmithSC, OxfordG, WuZ, et al. . The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res, 2006, 66(4): 1917-1922 PMID: 16488989

[37] SmithSC, TheodorescuD. The Ral GTPase pathway in metastatic bladder cancer: key mediator and therapeutic target. Urol Oncol, 2009, 27(1): 42-47 PMCID: 3904428 PMID: 19111797

[38] LeeKM1, JuJH, JangK, et al. . CD24 regulates cell proliferation and transforming growth factor β-induced epithelial to mesenchymal transition through modulation of integrin β1 stability. Cell Signal, 2012, 24(11): 2132-2142 PMID: 22800863